Abstract 80P
Background
The standard treatment for glioblastoma multiforme involves surgery followed by temozolomide (TMZ) treatment. However, many patients develop TMZ resistance either due to autophagic clearance of unwanted materials or reversal of TMZ-induced DNA alterations by methyl guanine o-methyl transferase. Additionally, other drugs are often ineffective because they cannot cross the blood-brain barrier (BBB). Hence, our objective is to repurpose FDA-approved drugs capable of crossing BBB and regulating autophagic pathways.
Methods
We identified differentially expressed genes regulating cellular processes in GBM, and used the Connectivity-MAP (C-Map) database to identify potential drugs, capable of reversing differentially expressed autophagy-associated genes. Following in-silico screening, we conducted cytotoxicity assays with selected drugs to evaluate IC50 values of drugs in 2-D and 3-D models. Additionally, immunoblotting and IF were performed to examine protein expression. Furthermore, we employed MDC staining to identify autophagic vacuoles, Annexin-PI to quantify apoptotic cells.
Results
Analysing GEO dataset, we identified top 10 dysregulated genes. Most downregulated genes were calcium signaling, while upregulated ones were PI3-Akt pathway. After identifying key genes and associated pathways, we used C-Map to identify top 5 drugs with high connectivity scores and BBB penetrance. They were assessed in vitro for their potential against GBM. Among them, Doxylamine and Gemfibrozil exhibited the best cytotoxicity, surpassing the standard drug TMZ. These drugs also hindered autophagic flux, verified by increased p62 and LC3B II proteins. Overexpression of PERK and CHOP confirmed ER stress-induced apoptosis. Furthermore, inhibition of Calmodulin, Calreticulin, and Calnexin post-drug-stress influenced the calcium signaling pathway. AnnexinV-PI assay demonstrated that increased ER stress and subsequent restriction of autophagic flux led to cell death.
Conclusions
Our research highlighted that doxylamine and gemfibrozil could serve as potential alternatives to TMZ for inducing apoptosis, by inhibiting autophagy, inducing ER stress, and generating ROS.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Indian Council of Medical Research (ICMR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Comprehensive analysis of clinical characteristics and germline status among colorectal cancer patients in a tertiary care center in Thailand
Presenter: NUTDANAI ROILA
Session: Cocktail & Poster Display session
Resources:
Abstract